Cefixime for the treatment of syphilis.
Phase 3
Not yet recruiting
- Registration Number
- PER-004-23
- Lead Sponsor
- IVERSITY OF SOUTHERN CALIFORNIA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Without starting enrollment
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
- Diagnosed cases of early syphilis with RPR titer =1:8 within 3 weeks prior to enrollment.
- 16 years of age or older.
- Individuals with HIV infection must be virologically suppressed or have a CD4 count = 350 cells/mm3.
Exclusion Criteria
- Pregnancy or a positive pregnancy test on the day of enrollment.
- Patients showing signs and symptoms of neurosyphilis.
- Concomitant antimicrobial therapy with activity against syphilis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cefixime's activity against Treponema pallidum in syphilis treatment?
How does cefixime compare to penicillin G in serological response rates for early syphilis patients?
Are there specific biomarkers that predict treatment success with cefixime over penicillin for syphilis?
What are the potential adverse events associated with cefixime therapy for syphilis and how are they managed?
What alternative cephalosporin antibiotics show promise in treating penicillin-resistant syphilis strains?